Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab in Pediatric Primary HLH
NCT03312751Phase 3Completed
- Sponsor
- Sobi
- Start
- Feb 2019
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of emapalumab in primary hemophagocytic lymphohistiocytosis (HLH), sponsored by Sobi. Started Feb 2019; status: completed.
02
Drugs
emapalumab
03
Conditions
primary hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT03312751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312751.